Celva Gmbh investment portfolio

Gelmetix Limited develops polymer‑gel therapeutic biomaterials for minimally invasive treatment of chronic lower back pain, restoring intervertebral disc function, and is advancing its DXM product through first‑in‑human clinical trials in France and Australia.

Jellagen Limited develops and manufactures "Collagen Type Zero," a jellyfish-derived biomaterial used for tissue engineering, regenerative medicine, and cell culture applications. The company supplies these products to the global scientific research, pharmaceutical, and medical device markets for use in areas such as wound healing and bone repair.